Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, has welcomed Simon Cooper, M.B.B.S. as Chief Medical Officer.   Dr. Cooper is an accomplished leader in drug development with success and a proven history across all phases of clinical development and in a variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Cooper most recently served as C...